http://www.cslbehring.com This news feed will provide you with a variety of CSL Behring press releases related to bleeding disorders. Thu, 04 Feb 2010 08:00:00 -0500 CSL Behring announced today the start of the global clinical trial program SWIFT (Studies with von Willebrand factor [VWF]/Factor VIII) to evaluate the pharmacokinetics, efficacy and safety of Biostate®, a low-volume, highly active, plasma-derived VWF/FVIII concentrate for the treatment of von Willebrand disease (VWD) and hemophilia A. The methodology behind the multi-center trials was detailed in a presentation at the 3rd Annual Congress of the European Association of Haemophilia and Allied Disorders (EAHAD) today. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1255923240834/prdetail.htm 1255923240834 Mon, 09 Nov 2009 10:13:19 -0500 CSL Behring has begun packaging Humate-P® (Antihemophilic Factor/von Willebrand Factor Complex [Human]) in a more user-friendly package based on customer market research. These packaging enhancements strive to improve the convenience of treatment for people with von Willebrand disease (VWD), the most common hereditary bleeding disorder in the United States. According to the Centers for Disease Control and Prevention, VWD affects approximately 1 to 2 percent of the U.S. population. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1255922661651/prdetail.htm 1255922661651 Thu, 29 Oct 2009 08:30:40 -0500 CSL Behring announced today the national winners of the 8th annual Gettin’ in the GameSM Junior National Championship (JNC). Developed by CSL Behring, provider of the hemophilia treatment Helixate® FS (Antihemophilic Factor, Recombinant), the JNC is a series of one-day events held throughout the country that provide hundreds of children with bleeding disorders the opportunity to participate in a golf and baseball competition. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1255922539436/prdetail.htm 1255922539436 Mon, 21 Sep 2009 09:00:00 -0500 Hemophilia A patients who require high doses of Helixate® FS, Antihemophilic Factor (Recombinant), can now benefit from greater convenience in administering their treatment, thanks to a new 3000 IU (international unit) dosage strength. CSL Behring announced today that this new dosage strength is available in the U.S., allowing many patients to reduce reconstitution time by eliminating the need to mix and pool multiple vials of Helixate FS. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1249870405858/prdetail.htm 1249870405858 Mon, 17 Aug 2009 20:53:30 -0500 CSL Behring announced today that Helixate® FS, Antihemophilic Factor (Recombinant), has been approved by the U.S. Food and Drug Administration (FDA) for routine prophylaxis in children with hemophilia A who are 16 years old or younger and do not have pre-existing joint damage. This new indication was granted by the FDA after determining Helixate FS is safe and effective for routine prophylaxis, which can reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1249870331760/prdetail.htm 1249870331760 Mon, 01 Jun 2009 08:00:00 -0500 CSL Behring, a global leader in the protein biotherapeutics industry, announced today the five grant winners of the 2009 Prof. Heimburger Awards. The grants of 20,000€ ($26,780 US) each were awarded to young clinicians conducting preclinical and/or clinical research in coagulation. Each project was chosen based on the scientific merit of the proposed initiative. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1242703942398/prdetail.htm 1242703942398 Mon, 04 May 2009 08:30:00 -0500 Hemophilia A patients and their treatment providers are now better able to manage their condition, thanks to an enhanced HeliTrax™ System from CSL Behring. Patients can now track and record their treatment progress in real time anywhere that internet access is available. By using a password-protected web interface, hemophilia A patients can easily input their treatment data and monitor their condition online even when they are not carrying their handheld electronic diary. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1241394169716/prdetail.htm 1241394169716 Fri, 17 Apr 2009 08:00:00 -0500 In recognition of the World Federation of Hemophilia’s (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program, CSL Behring has committed to donating to WFH two (2) million units of factor VIII concentrate (FVIII) each year for the next three (3) years. The donation, the total value of which will be approximately $2 million, will be made using coagulation factor concentrate with a minimum shelf-life of one year. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1236380045325/prdetail.htm 1236380045325 Thu, 02 Apr 2009 12:34:37 -0500 CSL Behring announced it will hold its next GameFaces™ challenge from April 14 through July 7, 2009. GameFaces is a family-oriented, online initiative for people with hemophilia A. The program is designed to encourage real-life physical activity through a series of customized challenges based on the individual’s age, disease severity and current level of physical activity. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1236380001660/prdetail.htm 1236380001660 Wed, 19 Nov 2008 11:50:10 -0500 CSL Behring announced today it launched the first challenge of GamesFaces™, a family-oriented online initiative for patients with hemophilia A, at the 60th Annual Meeting of the National Hemophilia Foundation (NHF). GameFaces is designed to encourage real-life physical activity through a series of three customized challenges based on the individual’s age, disease severity and current level of physical activity. Participants can now log on to the program website at www.HFSGameFaces.com, create their GameFaces character and begin the first challenge, which will run from today through January 10, 2009. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1225218729589/prdetail.htm 1225218729589 Wed, 01 Oct 2008 13:23:27 -0500 National Campaign Highlights Signs, Symptoms, Impact on Families of von Willebrand Disease. A group of mothers with VWD have joined together to focus attention on the need for more communication between mothers and their children about signs, symptoms and potentially severe health consequences of this disease. http://www.cslbehring.com/s1/cs/enco/1151517263302/news/1234773030958/prdetail.htm 1234773030958